Epilepsy CurrentsNeurodevelopmental Teratogenicity of Antiseizure Medications: The Good, the Bad, and Unknown

The NIH-funded MONEAD prospective trial (JAMA Neurology) followed children of women with epilepsy to age 6, finding no significant difference in verbal abilities compared to children of healthy women after covariate adjustment. However, exposure-dependent neurodevelopmental outcomes varied meaningfully across ASMs, reinforcing that drug choice and dosing, not epilepsy diagnosis alone, drive fetal risk.

Clinical Considerations

• Valproate and topiramate carry the highest neurodevelopmental risk: valproate is associated with 2-5x increased risk of intellectual disability and autism spectrum disorder; topiramate with 2-4x increased risk of intellectual disability
• Lamotrigine and levetiracetam — used by 78% of MONEAD participants — showed low neurodevelopmental risk; higher third-trimester lamotrigine levels correlated with slightly better verbal scores
• Carbamazepine data remain mixed; Danish adolescent data showed academic performance deficits at age 16 comparable in magnitude to valproate
• Absence of long-term data for newer ASMs does not equal safety — a distinction requiring explicit patient communication

Practice Applications

• Review ASM selection for all patients of reproductive age before conception, prioritizing agents with established low-risk profiles
• Discuss that dose optimization — high enough to prevent seizures, low enough to minimize fetal exposure — is the core therapeutic target in pregnancy
• Clarify with patients that a healthy newborn does not rule out later neurodevelopmental or behavioral sequelae
• Familiarize with MONEAD longitudinal data as the reference standard for pre-pregnancy ASM counseling

More in Epilepsy & Seizures